Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fate Therapeutics Inc FATE

Healthcare Biotechnology
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.


NDAQ:FATE - Post by User

Fate Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(229)
•••
Post by whytestockson Nov 19, 2024 8:31pm
46 Views
Post# 36320823

Perform Recommendation Issued On FATE By Oppenheimer

Perform Recommendation Issued On FATE By Oppenheimer
Breaking News: $FATE Perform Recommendation Issued On FATE By Oppenheimer2024-11-19 03:30:04 ET Oppenheimer analyst issues PERFORM recommendation for FATE on November 18, 2024 07:11PM ET. The previous analyst recommendation was Perform. FATE was trading at $2.27 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...FATE - Perform Recommendation Issued On FATE By Oppenheimer

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities